【レポートの概要（一部）】
1 Chapter 1: Introduction
1.1 Executive Summary
1.2 Topics Covered
1.3 Historical Revenue & Forecast Segmentation
1.4 Key Questions Answered
1.5 Key Findings
1.6 Methodology
1.7 Target Audience
1.8 Companies & Organizations Mentioned
2 Chapter 2: An Overview of Generic Drugs
2.1 What is a Generic Drug?
2.2 Reserve Engineering: How Are Generics Conceived?
2.3 The Concept of Bioequivalence: Are Generics the Same as Innovator Drugs?
2.3.1 What Defines Bioequivalence?
2.3.2 Acceptable Bioequivalence Ranges
2.4 The Question of Brand Quality: Are Generics as Efficient as their Innovator Counterparts?
2.5 Economics: Price Comparison
2.6 Brand Classification: Pure vs. Branded Generics
2.6.1 Pure (Non-branded) Generics
2.6.2 Branded Generics
2.6.3 Super Generics
2.7 Market Growth Drivers
2.7.1 Cost Effectiveness and Affordability
2.7.2 Low Insurance Premiums
2.7.3 Patent Expiry of Innovator Drugs
2.7.4 Political & Regulatory Support
2.7.5 Global Proliferation & Increasing Demand
2.8 Market Barriers
2.8.1 Patent Linkage: Delaying Product Launch
2.8.2 Complex Product Portfolios
2.8.3 Quality Control Issues
2.8.4 Intense Competitive Landscape
2.8.5 Resistance from Big Pharma Players
3 Chapter 3: Regulatory Landscape
3.1 Regional Outlook
3.1.1 Asia Pacific
3.1.2 Europe
3.1.3 Middle East & Africa
3.1.4 Latin & Central America
3.1.5 North America
3.2 International Initiatives
3.2.1 WHO Guidelines
3.2.2 IGDRP (International Generic Drug Regulators Pilot)
3.2.3 EMA (European Medicines Agency): Extending Collaboration beyond the EU
4 Chapter 4: Drug Class Availability & Leading Therapies
4.1 Drug Class Availability
4.1.1 Antibiotics
4.1.2 Cardiovascular & Hypertension
4.1.3 CNS (Central Nervous System)
4.1.4 Dermatology
4.1.5 Diabetes
4.1.6 Gastrointestinal
4.1.7 Hormonal Drugs
4.1.8 Onocology
4.1.9 Pain Relief
4.1.10 Respiratory
4.1.11 Rheumatology
4.1.12 Other Categories
4.2 Leading Generic Drugs
4.2.1 Acetaminophen (Paracetamol)
4.2.2 Alprazolam
4.2.3 Amlodipine
4.2.4 Amoxicillin
4.2.5 Asprin (Acetylsalicylic Acid)
4.2.6 Atenolol
4.2.7 Atorvastatin
4.2.8 Azithromycin
4.2.9 Bendroflumethiazide
4.2.10 Betamethasone Dipropionate
4.2.11 Candesartan
4.2.12 Clavulanic Acid
4.2.13 Clopidogrel
4.2.14 Dexamfetamine
4.2.15 Diclofenac
4.2.16 Doxycycline
4.2.17 Enalapril
4.2.18 Enoxaparin Sodium
4.2.19 Esomeprazole
4.2.20 Fentanyl
4.2.21 Fenofibrate
4.2.22 HCTZ (Hydrochlorothiazide)
4.2.23 Ibuprofen
4.2.24 Lansoprazole
4.2.25 Levothyroxine Sodium
4.2.26 Lisinopril
4.2.27 Losartan
4.2.28 Metformin
4.2.29 Methylphenidate
4.2.30 Methotrexate
4.2.31 Metoprolol
4.2.32 Omeprazole
4.2.33 Pantoprazole
4.2.34 Perindopril
4.2.35 Ramipril
4.2.36 Rosuvastatin
4.2.37 Salbutamol (Albuterol)
4.2.38 Simvastatin
4.2.39 Valsartan
4.2.40 Venlafaxine
4.2.41 Others
5 Chapter 5: Generic Drugs Industry Roadmap & Value Chain
5.1 Industry Roadmap
5.1.1 2015 – 2020: Overtaking Innovator Drugs
5.1.2 2020 – 2025: The Era of Generic Biologics
5.1.3 2025 – 2030 & Beyond: Evolving Regulatory Landscape
5.2 Value Chain
5.2.1 API Manufacturers & Enabling Technology Providers
5.2.1 Generic Drug Manufacturers
5.2.2 Innovator Pharmaceutical Companies
5.2.3 Regional Distributors
5.2.4 Healthcare Providers, Pharmacies & Drug Stores
6 Chapter 6: Key Market Players
6.1 Abbott Laboratories
6.2 AbbVie
6.3 ACETO Corporation
6.4 Acino Holding
6.5 Actavis
6.6 Actelion
6.7 Adcock Ingram
6.8 Ajinomoto
6.9 Akron
6.10 Alexion Pharmaceuticals
6.11 Alfa Wasserman
6.12 Amgen
6.13 AMRI (Albany Molecular Research, Inc.)
6.14 Amneal Pharmaceuticals
6.15 Apotex
6.16 ASKA Pharmaceutical Company
6.17 Aspen Holdings
6.18 Astellas Pharma
6.19 AstraZeneca
6.20 Aurobindo Pharma
6.21 Baxter BioScience
6.22 Bayer AG
6.23 BD (Becton, Dickinson and Company)
6.24 Biogen Idec
6.25 Biocon
6.26 Boehringer Ingelheim
6.27 BMS (Bristol-Myers Squibb)
6.28 Cadila Healthcare (Zydus Cadila)
6.29 Cadila Pharmaceuticals
6.30 Celgene Corporation
6.31 Chiesi Farmaceutici
6.32 Chugai Pharmaceutical Company
6.33 Claris Lifesciences
6.34 Cipla
6.35 Coherus BioSciences
6.36 Consort Medical
6.37 Daiichi Sankyo
6.38 Dong-A Pharmaceutical
6.39 Dr. Reddy’s Laboratories
6.40 Eisai Company
6.41 Eli Lilly and Company
6.42 Endo International
6.43 ESTEVE Group
6.44 Eurofarma Laboratorios
6.45 Ferring Pharmaceuticals
6.46 Fresenius Kabi
6.47 Fujifilm Pharma Company
6.48 Fuji Pharma Company
6.49 Galderma
6.50 Galenika
6.51 Gedeon Richter
6.52 Genepharm
6.53 Gilead Sciences
6.54 Glenmark Pharmaceuticals
6.55 Grifols
6.56 Gruenenthal Group
6.57 GSK (GlaxoSmithKline)
6.58 Hanmi Pharmaceutical Company
6.59 Hetero Drugs
6.60 Hikma Pharmaceuticals
6.61 Hospira
6.62 Impax Laboratories
6.63 Ipsen
6.64 JT (Japan Tobacco)
6.65 Jazz Pharmaceuticals
6.66 Johnson & Johnson
6.67 Kaken Pharmaceutical Company
6.68 Kaneka Corporation
6.69 Kowa Company
6.70 Kremers Urban Pharmaceuticals
6.71 Krka (Krka, d. d.)
6.72 Kyowa Hakko Kirin Company
6.73 Laboratorios Roemmers
6.74 Leo Pharma
6.75 Les Laboratoires Servier
6.76 Lundbeck (H. Lundbeck A/S)
6.77 Lupin
6.78 Mallinckrodt
6.79 Maruho Company
6.80 Meda
6.81 Meiji Holdings
6.82 Menarini Group
6.83 Merck and Co.
6.84 Merck KGaA
6.85 Merz Pharma
6.86 Mitsubishi Tanabe Pharma
6.87 Mitsui & Company
6.88 Mylan
6.89 Natco Pharma
6.90 Nichi-Iko Pharmaceutical Company
6.91 Nippon Kayaku
6.92 Nippon Shinyaku
6.93 Nipro Pharma Corporation
6.94 Novo Nordisk
6.95 Ono Pharmaceutical Company
6.96 Orion Corporation
6.97 Otsuka Holdings Company
6.98 Par Pharmaceutical Companies
6.99 Perrigo Company
6.100 Pfizer
6.101 Pharmstandard
6.102 Pierre Fabre (Laboratoires Pierre Fabre)
6.103 Piramal Enterprises
6.104 Pliva (Pliva d.d.)
6.105 Prasco Laboratories
6.106 Purdue Pharma
6.107 Ranbaxy Laboratories
6.108 Recordati
6.109 Regeneron Pharmaceuticals
6.110 Roche Holding (F. Hoffmann-La Roche)
6.111 Salix Pharmaceuticals
6.112 Samsung Group
6.113 Sandoz International (Novartis International)
6.114 Sanofi
6.115 Santen Pharmaceutical Company
6.116 Sawai Pharmaceutical Company
6.117 Seikagaku Corporation
6.118 Sequent Scientific
6.119 Shionogi & Company
6.120 Shire
6.121 Sigma-Tau
6.122 STADA Arzneimittel
6.123 Strides Arcolab
6.124 Sumitomo Dainippon Pharma Company
6.125 Sun Pharmaceutical Industries
6.126 Taisho Pharmaceutical Holdings Company
6.127 Takeda Pharmaceutical Company
6.128 Teijin
6.129 Teva Pharmaceutical Industries
6.130 The Medicines Company
6.131 Torrent Pharmaceuticals
6.132 Towa Pharmaceutical Company
6.133 UCB
6.134 United Therapeutics Corporation
6.135 Valeant Pharmaceuticals International
6.136 Vertex Pharmaceuticals
6.137 Wockhardt
7 Chapter 7: Market Analysis & Forecasts
7.1 Global Outlook of Generic Drugs
7.2 Segmentation by Brand Classification
7.2.1 Pure (Non-branded) Generics
7.2.2 Branded Generics
7.2.3 Super Generics
7.3 Segmentation by Therapeutic Area
7.3.1 Antibiotics
7.3.2 Cardiovascular & Hypertension
7.3.3 CNS
7.3.4 Dermatology
7.3.5 Diabetes
7.3.6 Gastrointestinal
7.3.7 Hormonal Drugs
7.3.8 Oncology
7.3.9 Pain Relief
7.3.10 Respiratory
7.3.11 Rheumatology
7.3.12 Others
7.4 Segmentation by Region
7.4.1 Asia Pacific
7.4.2 Europe
7.4.3 Middle East & Africa
7.4.4 Latin & Central America
7.4.5 North America
7.5 Top Country Markets
7.5.1 Brazil
7.5.2 Canada
7.5.3 China
7.5.4 Egypt
7.5.5 France
7.5.6 Germany
7.5.7 Greece
7.5.8 India
7.5.9 Israel
7.5.10 Italy
7.5.11 Japan
7.5.12 Mexico
7.5.13 Netherlands
7.5.14 Poland
7.5.15 Portugal
7.5.16 Russia
7.5.17 Saudi Arabia
7.5.18 South Africa
7.5.19 South Korea
7.5.20 Spain
7.5.21 Switzerland
7.5.22 Taiwan
7.5.23 Turkey
7.5.24 UK
7.5.25 USA
8 Chapter 8: Conclusion & Strategic Recommendations
8.1 Why is the Market Poised to Grow?
8.2 Are Generic Drugs Becoming Expensive?
8.3 Competitive Industry Landscape: Acquisitions, Alliances & Consolidation
8.4 High Profile Recalls: What is the Impact on the Market?
8.5 Lower-Cost Countries: Increasing R&D and Manufacturing Investments
8.6 Geographic Outlook: Which Countries Offer the Highest Growth Potential?
8.7 Prospects of Biosimilars
8.7.1 How Big is the Biosimilars Opportunity?
8.7.2 Regulatory Status
8.8 Strategic Recommendations
8.8.1 Generic Drug Manufacturers
8.8.2 Innovators
【レポート販売概要】
■ タイトル：後発医薬品の世界市場：機会、課題、戦略、市場予測■ 英文：The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts
■ 発行日：2015年2月
■ 調査会社：Signals and Systems Telecom
■ 商品コード：DATA5022408
■ 調査対象地域：グローバル
- 神経症（Neuropathy）治療のグローバル臨床試験動向（2014年下半期）Neuropathy Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of tri …
- ガスタービンの世界市場予測および動向（～2020）The global gas turbines market is projected to grow at a CAGR of 3.9% from 2015 to 2020, to reach a value of USD 19.6 Billion by 2020. Increasing availability of natural gas owing to the shale gas boom and higher efficiency & lower carbon emission characteristics of natural gas-fired power plants are the major factors driving the gas turbines market. Applications of gas turbines are not limited to …
- 軸性脊椎関節炎（Axial SpA）治療薬のグローバル治験動向（2015年上半期）Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015" provides data on the Axial Spondyloarthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Axial Spondyloarthritis. It includes an overview of the trial numbers …
- ハイブリッド電源ソリューションの世界市場予測（～2021）：発電種類別（太陽光・ディーゼル、風力・ディーゼル、太陽光・風力・ディーゼル）、電力定格別（10 kWまで、11 kWから100 kW、100 kW以上）、エンドユーザー別（住宅、商業、通信）、地域別“The hybrid power solutions market is projected to grow at a CAGR of 8.1% from 2016 to 2021” The hybrid power solutions market is projected to reach USD 689.5 million by 2021, growing at a CAGR of 8.1% from 2016 to 2021. Hybrid power solutions are used in residential, commercial, telecom and other industries. Growth in hybrid power generation in off-grid sites, reliable power generation with minim …
- パラキシレンの世界市場：用途及び地域別分析The global paraxylene market, in terms of value, is estimated to grow at a CAGR of 11.3% from 2014 to 2019. Asia-Pacific held the largest share 83.0% of the global paraxylene market in 2014, followed by the North American segment, which is expected to grow at a CAGR of 9.3% during the forecast period of 2014 to 2019. In this report, the global paraxylene market has been broadly classified on the b …
- カタールの防衛市場動向Product Synopsis This report is the result of SDI's extensive market and company research covering the Qatari defense industry, and provides detailed analysis of both historic and forecast defense industry values including key growth stimulators, analysis of the leading companies in the industry, and key news. Introduction and Landscape Why was the report written? The Future of the Qatari Defense …
- イギリスのスマートホームM2M通信市場About smart home A smart home comprises an internal network, home automation, and intelligent control. It is commonly defined as a home that is equipped with digital devices and home appliances. These devices and appliances are interconnected with each other and can be remotely accessed by end-users with the help of their smartphone or tablet from a remote location. Smart home offers a wide variet …
- 世界の微量栄養素市場動向及び予測（～2018）The essential elements needed by plants are known as micronutrients; they are required in trace amounts. Although they are in small quantity, they are as important as macronutrients. Micronutrients include copper (Cu), boron (B), manganese (Mn), chlorine (Cl), iron (Fe), molybdenum (Mo), and zinc (Zn). They have acquired a lot of attention in the agriculture in recent years. Now it is possible to …
- エレクトロニック・フライト・バッグ（EFB）の世界市場予測（～2020）The electronic flight bag (EFB) market is projected to grow from USD 2.73 Billion in 2015 to USD 5.06 Billion by 2020, at a CAGR of 13.09% during the forecast period. The major factors for the growth of the EFB market are increase in need for fuel efficient aircraft, reduction of cost and improved operational efficiency, reduction in aircraft maintenance cycle and real-time access to information. …
- 電動推進式人工衛星の世界市場ABSTRACTAbout Electric Propulsion Satellite Electric-powered satellite propulsion system employs electrical energy to change the velocity of spacecraft. Most all-electric satellite propulsion systems work by electrically expelling propellant or reaction mass at high speed. The hybrid propulsion systems engage both chemical and electrical propulsion technologies. Conventional electric thrusters use …
- Flexible Glass Markets, 2014 and BeyondFlexible glass as originally promoted seemed to be a miracle material; one that combined the virtues of glass and the virtues of plastic. However, during 2013, flexible glass seems to have stumbled. Ambitious talk of millions of flexible mobile displays based on flexible glass substrates and cover glass have given way to more restrained projections in which initial uses for flexible glass are more …
- 世界の2-エチルヘキサノール(2-EH)市場動向（～2018）2-EH is an oxo alcohol which was earlier employed in the industry as a plasticizer alcohol for manufacturing various phthalate plasticizers, but as the restrictions were imposed on the use of phthalate plasticizers by various regulatory bodies around the world, the consumption trends changed significantly in the recent years. Currently, major application areas of 2-EH are as a precursor for manufa …
- 世界のスマートグリッド産業における遠隔端末装置（RTU）市場About remote terminal unit (RTU) in smart grid A remote terminal unit is a control device that helps the master device (SCADA) monitor and communicate with grid devices placed across different geographical locations. They can be used in a wide variety of electrical and process automation devices where SCADA is required to monitor and control equipment. RTUs are used to collect data from equipment …
- 女性衛生用品の世界市場：生理用ナプキン、おりものシート、タンポンAbout feminine hygiene Feminine hygiene products are used by women during their menstrual cycle or during vulva discharge. These products are available in both disposable and washable forms. Technavio's analysts forecast the global feminine hygiene market to grow at a CAGR 4.92% in terms of revenue during 2014-2019. [Covered in this report] The global feminine hygiene market can be segmented into …
- プラスターボードの世界市場：標準型/耐火性/防音性/耐湿性/耐熱性/耐衝撃性/特殊プラスターボードPlasterboard is an extensively used building material, which can be defined as a thin rigid board, in the form of a layer of gypsum core compressed between two thick sheets of recycled paper, used for forming and covering walls and ceilings. It is also referred to as a wallboard or drywall as it involves a dry construction process for its installation. The market for plasterboard is driven by the …
